ArticleWorld journal of gastrointestinal oncology2024
Is sarcopenia effective on survival in patients with metastatic gastric cancer?
Article in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between gastric cancer and sarcopenia: a scoping review.Frontiers in oncology · 2025Pooled it
- Thoracic Skeletal Muscle Attenuation Predicts Sex-Specific Mortality After Coronary Artery Bypass Grafting-Sex-Specific Insights into Risk Stratification and Frailty Assessment.Medical sciences (Basel, Switzerland) · 2026Article
- Is myopenia sufficient to diagnose sarcopenia?The oncologist · 2026Article
- Combined Inflammatory Burden Index and hand grip strength for prognostic assessment in gastric cancer patients: a multicenter cohort study.Frontiers in nutrition · 2026Article
- Muscle size and muscle fat infiltration in patients with newly diagnosed prostate cancer: a case-control study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is a progressively diminishing state characterized by the reduction of muscle mass and density, which is frequently observed in malignancies of solid organs.
aimTo assess how sarcopenia affects the overall survival of individuals who have been diagnosed with metastatic gastric cancer.
methodsThe study retrospectively included individuals who had been diagnosed with metastatic gastric cancer between January 2008 and December 2020. Sarcopenia was identified through the calculation of the average Hounsfield units (HUAC) using computed tomography (CT) images taken at the time of diagnosis in patients.
resultsA total of 118 patients with metastatic gastric cancer were evaluated. Sarcopenia was detected in 29 patients (24.6%). The median survival of all patients was 8 (1-43) mo. The median survival of patients with sarcopenia was 2 mo, while it was 10 mo for those without sarcopenia (
conclusionSarcopenia has been observed to impact survival outcomes in various types of solid tumor cancers. Sarcopenic patients can be identified in a short time, easily and inexpensively, by HUAC measurements from CT images used for diagnosis, and survival could be promoted with nutritional support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.